skip to main content

HCV DAA Treatment — RACP Adult Medicine MCQ

Instant feedback + full explanation. One question, done properly.

EasyGastroenterology & HepatologyHCV DAA TreatmentRACP Adult Medicine

A 60-year-old man with newly diagnosed chronic hepatitis C (genotype not tested) has no cirrhosis on FibroScan (5.5 kPa). He takes no regular medications. What is the recommended pan-genotypic treatment?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Glecaprevir/pibrentasvir for 8 weeks

For treatment-naïve chronic HCV without cirrhosis, glecaprevir/pibrentasvir (Maviret) for 8 weeks is the shortest pan-genotypic regimen available. SVR rates exceed 97%. Sofosbuvir/velpatasvir for 12 weeks is an equally effective alternative. The 8-week course of glecaprevir/pibrentasvir is preferred for non-cirrhotic patients due to shorter duration and excellent tolerability. Both are PBS-listed in Australia. Genotype testing is no longer required when using pan-genotypic regimens.

Reference: Gastroenterological Society of Australia – 2022 – HCV Consensus; PBS – 2025 – DAA Listings